



Accelerero Receives EU Eurostars Funding Supporting a Gene Therapy for the Treatment of Lypodystrophy

Berlin, 22 February 2021

Accelerero Bioanalytics GmbH ("Accelerero") is awarded EUR 136,500 in project grants to support research and development of a gene therapy targeting lypodystrophy.

The project called CGT2 is headed by Scandinavian's leading gene therapy company CombiGene AB, Lund, Sweden ("CombiGene"), and aims to develop an AAV-based gene therapy for the treatment of the rare disease partial lipodystrophy.

The CGT2 project consortium includes a research group of the University of Hamburg ("Universitätsklinikum Hamburg Eppendorf") with its expertise in lipid research.

EU's Eurostars program is the largest international financing program for SMEs wishing to cooperate on R&D. Competition is high and funding is only allocated to projects that come high in the rankings. Eurostars has now allocated a total of EUR 882,500 in development funding to the CGT2 project.

Accelerero will be responsible for the development of human monoclonal antibodies targeting CGT2. One integral part is the setup and development of appropriate immunoassays as tools for in vitro as well as in vivo CGT2 proof-of-concept characterization.

For additional information on Accelerero's services, please feel free to use our website contact form, or send us an email to [service\(at\)accelero-bioanalytics.com](mailto:service@accelero-bioanalytics.com). The Accelerero team will be happy to assist you.

Accelerero Bioanalytics GmbH
Center for Biotechnology and Environment
Volmerstrasse 9A
12489 Berlin
GERMANY

Primary Contact:
Christian Lange, Founder & Managing Director
Telephone +49 30 610 910 300

qPCR
Biodistribution
ELISA
EliSpot / FluoroSpot
Flow cytometry
Multiplex immunoassays
Multiplex miRNA assays
Cell culture
Microbiology
GLP trainings & seminars

Follow us on



Read binding-assay.com for blog and case studies.

